2017 AHA Heart Science Forum Innovation Challenge Award 1st Place Winner and the 1st Annual Samsung Digital Health Summit Technology Pitch Contest Award 1st Place Winner

Multifunction Cardiogram Technology or the MCG was engineered to answer a fundamental question and solve a critical problem. The question was if we could apply the mathematic principals of Lagrangian Mechanics to build an objective machine powered digital diagnostic paradigm to forever change the face of the future of diagnostic medicine, as we know it. The problem we wanted to solve once and for all was the intractable dilemma of poor diagnostic accuracy caused by the deeply fl awed system designs of the conventional imaging and EKG/EEG tools used throughout the industry. Thus, starting from the very fi rst moment, we had to learn from where others failed.


Introduction
Multifunction Cardiogram Technology or the MCG was engineered to answer a fundamental question and solve a critical problem. The question was if we could apply the mathematic principals of Lagrangian Mechanics to build an objective machine powered digital diagnostic paradigm to forever change the face of the future of diagnostic medicine, as we know it. The problem we wanted to solve once and for all was the intractable dilemma of poor diagnostic accuracy caused by the deeply fl awed system designs of the conventional imaging and EKG/EEG tools used throughout the industry.
Thus, starting from the very fi rst moment, we had to learn from where others failed.
During the design phase of the fi rst generation of our technology, our team performed an extensive review of all existing technology that currently works via the processing of ECG signals. We reviewed the methods designed to improve the traditional 12-lead ECG, from the exotic signal average EKG (failed clinically), vector EKG (also failed) all the way to mapping using 86 EKG leads (never entered clinical use, too cumbersome). Following the meta-analysis of over one million published papers, we concluded that the traditional ECG waveform analysis has fundamental, fatal design fl aws which doom those who attempt to improve its performance with dismal failures in the real world settings. We believe that the traditional "expert dependent" ECG waveform analysis had arrived at a dead-end.
In our research in the early 1990s, we also discovered another unpleasant, and frankly disturbing truth: most, if not all, of the published peer review journal articles we had to sift through were based on multitudes of biases, fraudulent claims, and fl at out wrong self-fulfi lling conclusions [1][2][3], that lack the independent, unpaid verifi cation and validation process that we absolutely insisted on to validate the MCG a meta-analysis of ~400,000 patients that underwent coronary angiograms independent of our own analysis, and by the end of the study, the overall diagnostic yield was 38% [5]. In 2014, another large study of ~600,000 patients underwent coronary angiogram in more than 224 US hospitals, also independent of us, providing an overall yield of 40% [6]. Even the highly regarded Functional MRI has not been spared of criticism [7]. The MCG not only analyzes the heart but the whole of the electronic network, or the entire cardiovascular "intranet", that controls the cardiovascular system in its entirety, interacting with all these internal and external factors using multiple mathematical functions to extract and analyze the interactions or communications that occur throughout the system. Each

No quid pro quo (or money changing hands with
any of the investigators) for double-blinded, independently monitored by a third party trial monitor, replicable trial design and protocols with reproducible data analysis.
To this effect, multiple double-blind independent prospective clinical trials conducted in Eight Countries, USA, Germany, Japan, India, China, Singapore, Myanmar, and Malaysia from Three Continents to Validate MCG thousands of patients, since 2002. The fi nal results placed MCG's overall accuracy at a reproducible rate of over 90%. When the results of MCG are combined with serum biomarkers such as HbA1c, hBNP, Abnormal Glucose levels, or LDL levels, the accuracy approaches 100% for the detection of coronary artery ischemia from very early stages to the very severe late stages, as well as the natural recovery stages of the disease. This along with reported negative predictive values between 95% to 99% (References of independently published clinical validation trial articles available upon request).
To demonstrate what we have accomplished to thoroughly verify and validate MCG, most recently, our colleagues from Japan and many other countries have conducted independent meta-analysis of the data of thousands of patients collected over the past fi ve years from multiple centers, and concluded the following in "A Phase Five Post Market Surveillance Data Meta-Analysis Concludes" (pending publication): • MCG is 3 to 5 times more accurate than conventional ECG • MCG is 2 to 3 times more accurate than echocardiogram • MCG is 2 to 3 time more accurate than nuclear, echo, ECG, and pharmacological stress tests • MCG is reproducibly "compatible" with the current platinum standard -Coronary Angiography plus Functional Fractional Reserve, Classical Syntax Score or Functional Syntax Scores with replicable results. However, they also concluded that MCG may be much better in areas that coronary angiography cannot detect, such as small vessel micro vascular disease and metabolic heart disease due to type two diabetes.
Below are some examples of the unique capabilities of MCG the physician communities have discovered over the past fi ve years: • MCG can quantify the degrees of functional loss of the myocardium and its interaction with other factors such as blood supply, metabolic disorders, such as diabetes, heart failure of any cause, and many infl ammatory, infectious, or neural hormonal systemic disorders, etc.
• MCG can detect low, intermediate and high degrees of ischemia due to all stages of coronary artery disease from very early (as little as 30% coronary artery narrowing to 100% occlusion with or without the collaterals).
• MCG is just as accurate for people with low risks as it is In truth, with all of this being considered, one can say that we here stand at the precipice of potentially eliminating human bias from cardiovascular diagnosis and clinical trial data analysis reporting for the good of both doctors and patients the world over. When Professor John Ioannidis asked where the practice of evidence-based medicine could be undeniably helpful to human beings and society at large, he questioned what remote corner of the world he'd have to go to see it happen in person. In truth, the answer was much simpler than he likely thought. It is here, with us, with this company, with this technology. In fact, we believe that our peer review published clinical validation work is one of the very rare and few examples amongst 30+ million articles published in the medical literature in the past 10 to 15 years! All that needs to happen now is its wider adoption into the open market so that all may reap its benefi ts.